[go: up one dir, main page]

PE20252585A1 - Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos - Google Patents

Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos

Info

Publication number
PE20252585A1
PE20252585A1 PE2025001718A PE2025001718A PE20252585A1 PE 20252585 A1 PE20252585 A1 PE 20252585A1 PE 2025001718 A PE2025001718 A PE 2025001718A PE 2025001718 A PE2025001718 A PE 2025001718A PE 20252585 A1 PE20252585 A1 PE 20252585A1
Authority
PE
Peru
Prior art keywords
grk2
protein
degradation
coupled receptor
receptor kinase
Prior art date
Application number
PE2025001718A
Other languages
English (en)
Inventor
Zuling Xu
Xin Cai
Original Assignee
Nanjing Huanbo Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Huanbo Biotechnology Co Ltd filed Critical Nanjing Huanbo Biotechnology Co Ltd
Publication of PE20252585A1 publication Critical patent/PE20252585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a compuestos de degradacion de la cinasa 2 del receptor acoplado a proteinas G (GRK2) o una sal farmaceuticamente aceptable, un isomero, un isotopo, un profarmaco, un solvato, o un polimorfo de este, composiciones farmaceuticas que comprenden los mismos, kits que comprenden los mismos, y usos de los mismos para prevenir o tratar enfermedades o afecciones al menos parcialmente medicadas por GRK2 o que pueden beneficiarse de la degradacion de GRK2. Se trata de un compuesto de Formula (1): GBM-DT (1) o una sal farmaceuticamente aceptable, un isomero, un isotopo, un profarmaco, un solvato o un polimorfo de este; en donde: GBM es un resto de union a GRK2; y DT es una etiqueta de degradacion que tiene capacidad de union a la ligasa E3.
PE2025001718A 2023-02-10 2024-02-09 Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos PE20252585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023075491 2023-02-10
PCT/CN2024/077138 WO2024165075A1 (en) 2023-02-10 2024-02-09 G protein-coupled receptor kinase 2 (grk2) degradation compounds and use thereof

Publications (1)

Publication Number Publication Date
PE20252585A1 true PE20252585A1 (es) 2025-11-11

Family

ID=92262085

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025001718A PE20252585A1 (es) 2023-02-10 2024-02-09 Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos

Country Status (8)

Country Link
EP (1) EP4662211A1 (es)
KR (1) KR20250139885A (es)
CN (1) CN120917020A (es)
AU (1) AU2024218793A1 (es)
IL (1) IL322532A (es)
MX (1) MX2025009366A (es)
PE (1) PE20252585A1 (es)
WO (1) WO2024165075A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
CA3174266A1 (en) * 2020-05-27 2021-12-02 Grazia Piizzi Grk2 inhibitors and uses thereof
WO2022159688A1 (en) * 2021-01-22 2022-07-28 Cygnal Therapeutics, Inc. Degraders of grk2 and uses thereof
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
EP4347860A1 (en) * 2021-06-04 2024-04-10 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023129564A1 (en) * 2021-12-27 2023-07-06 Cygnal Therapeutics, Inc. Degraders of grk2 and uses thereof

Also Published As

Publication number Publication date
CN120917020A (zh) 2025-11-07
IL322532A (en) 2025-10-01
EP4662211A1 (en) 2025-12-17
AU2024218793A1 (en) 2025-08-21
KR20250139885A (ko) 2025-09-23
MX2025009366A (es) 2025-11-03
WO2024165075A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
PE20240775A1 (es) Compuestos antivirales
MX2024011697A (es) Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)
CO2021017202A2 (es) Compuestos tricíclicos
UY39799A (es) Compuestos de pirrolil–sulfonamida
PE20220970A1 (es) Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
PE20251667A1 (es) Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv
MX2024011179A (es) Compuestos multiciclicos
DOP2025000009A (es) Inhibidores de acc novedosos
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
PE20252585A1 (es) Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos
PE20251177A1 (es) Inhibidores heterociclicos de sik
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
CL2022002641A1 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
MX2024011935A (es) Derivado de isoxazol heterocíclico, composición farmacéutica y uso
PE20251236A1 (es) Formas cristalinas y sales de un agonista del receptor muscarinico
PE20240585A1 (es) Compuestos pirimidinicos para usar como inhibidores de map4k1
MX2024008745A (es) Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo.
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2023010044A (es) Compuesto para el tratamiento de trastornos cognitivos.
MX2024008929A (es) Heterociclos biciclicos sustituidos como inhibidores de malt-1 referencia cruzada a la solicitud relacionada.
AR133698A1 (es) COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS
AR129556A1 (es) Compuestos químicos
UY39722A (es) Nuevos derivados de heteroaril aminopropanol